The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
While the implementation of ICH Q12 tools and enablers across the US, EU, Japan, Canada, Switzerland and other ICH member countries is under way, it is recognized that the global regulatory authorities are at different stages of incorporation of ICH Q12 principles and tools, which in itself can pose challenges. This session will be focused on real life examples pertaining to ECs, PACMPs, PLCM documents and the PQS from global ICH Q12 related pilot programs and submissions to health authorities to help understand the benefits and challenges associated with this enhanced framework. The understanding gained would facilitate effective, predictive management and operational flexibility of post-approval lifecycle changes thus enabling timely access of high quality, safe, and effective medicines to patients while reducing unnecessary cost, time, and burden on industry and regulators.
In-depth analytical characterization of biological drugs and vaccines is important to aid in their development, and innovation in analytical technologies is crucial for the advancement of complex modalities…
Drug delivery technologies are evolving to support the delivery of drugs that balance enhanced safety and efficacy profiles with ease of use. With rapid evolution comes challenges to implementation of new devices and technologies…